LIVE VIDEO: News10 Midday    Watch
 

FDA allows generic version of scarce cancer drug

3:20 PM, Feb 4, 2013   |    comments
  • Share
  • Print
  • - A A A +

WASHINGTON (AP) - Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies. 

The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments. 

The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker. 

Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.

The Associated Press

Most Watched Videos